Yahoo Finance report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
Why AUPH Stock dropped -3.25% Today — RQD Quant Desk Flash
Aurinia Pharmaceuticals Inc (AUPH) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (89% profit margin, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AUPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $16.65 (-3.25% 1D, market cap $2.22B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, AUPH ranks #42 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AUPH compare to XNCR and VERA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AUPH carries a Roarable B (74/100 RQD), trailing P/E of 8.0x, gross margin of 88.5%, and ROIC of 16.5%. By comparison, XNCR (Xencor Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -21.3%, cap $2.22B) and VERA (Vera Therapeutics Inc. (Class A)) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.23B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AUPH?
▼
Per AUPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001600620), Aurinia Pharmaceuticals Inc generated $283.1M in revenue (+20.4% YoY), $287.2M in net income, and $135.7M in free cash flow against $751.6M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 8.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)
⚔️ Adversarial Opposing Case: Why the AUPH Bull Thesis Could Fail
Even with a 74/100 (B) score, AUPH faces multiple-compression risk if 8.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 86.0% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($16.50) or 200D SMA ($15.67) invalidates the momentum regime and cuts Target Base ($17.85) toward Bear Floor ($13.65).
Why AUPH Stock dropped -3.25% Today — RQD Quant Desk Flash
Aurinia Pharmaceuticals Inc (AUPH) dropped -3.25% to $16.65, trading at 60% of its 52-week range ($12.79 – $19.25). High-quality cash engine (89% profit margin, 17% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 60% of its 52-week range ($12.79 – $19.25) with RSI-14 at 49.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.1% around $16.65 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 88.5% gross margin and $135.7M annual free cash flow.
StockInvest.us report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
EDMONTON, Alberta (AP) — EDMONTON, Alberta (AP) — Aurinia Pharmaceuticals Inc. (AUPH) on Friday reported third-quarter net income of $31.
EDMONTON, Alberta, October 30, 2026--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress
Scheduled RQD Strong Buys & Whale Accumulation Briefing (AUPH Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
AUPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +20.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AUPH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AUPH. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AUPH)
1. Head-to-Head Health Care Peer Comparison (AUPH vs. XNCR, VERA, PRGO, HRMY)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aurinia Pharmaceuticals Inc (AUPH) ranks #42 by composite RQD confidence (74/100, grade B) and #240 by equity capitalization ($2.22B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with AUPH at 74/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AUPH
ACTIVE
Aurinia Pharmaceuticals Inc | B | 74/100 | 8.0x | 88.5% | 16.5% | -3.25% | $2.22B | Benchmark Subject |
| XNCR Xencor Inc. | D | 47/100 | — | — | -21.3% | +2.09% | $2.22B | /xncr-vs-auph → |
| VERA Vera Therapeutics Inc. (Class A) | E | 31/100 | — | — | -35.0% | +1.47% | $2.23B | /vera-vs-auph → |
| PRGO Perrigo Company plc | D | 49/100 | — | 35.1% | -13.6% | -0.75% | $2.19B | /prgo-vs-auph → |
| HRMY Harmony Biosciences Holdings Inc. | A | 86/100 | 14.2x | 77.2% | 63.0% | +0.44% | $2.26B | /hrmy-vs-auph → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001600620In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aurinia Pharmaceuticals Inc (AUPH) reported GAAP revenue of $283.1M (+20.4% vs. FY2024 revenue of $235.1M , and +61.3% cumulative change since FY2023) , GAAP net income of $287.2M, operating cash flow of $135.7M, and free cash flow of $135.7M (+205.6% YoY). On the balance sheet, AUPH closed FY2025 with $751.6M in total assets against $0 in total debt (Altman Z-Score: 8.33, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $283.1M | $287.2M | $135.7M | $135.7M | $751.6M | — |
| FY2024 (FY) | 2024-12-31 | $235.1M | $5.8M | $44.4M | $44.4M | $550.6M | — |
| FY2023 (FY) | 2023-12-31 | $175.5M | -$78.0M | -$33.5M | -$33.5M | — | — |
3. AUPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AUPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $16.65 (-3.25% 1D, market cap $2.22B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, AUPH ranks #42 in composite RQD confidence.
How does AUPH compare to XNCR and VERA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AUPH carries a Roarable B (74/100 RQD), trailing P/E of 8.0x, gross margin of 88.5%, and ROIC of 16.5%. By comparison, XNCR (Xencor Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -21.3%, cap $2.22B) and VERA (Vera Therapeutics Inc. (Class A)) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.23B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AUPH?
Per AUPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001600620), Aurinia Pharmaceuticals Inc generated $283.1M in revenue (+20.4% YoY), $287.2M in net income, and $135.7M in free cash flow against $751.6M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AUPH trading relative to its 50-day, 200-day, and 52-week technical levels?
AUPH last traded at $16.65 (-3.25% on volume of 960,884 shares), positioning the stock +0.91% above its 50-day simple moving average ($16.50) and +6.25% above its 200-day simple moving average ($15.67). Across its 52-week range of $12.79 to $19.25, AUPH sits at the 59.8% percentile with a 14-day RSI of 49.1 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($15.63 to $17.67).
AUPH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AUPH stock moving today?
Why AUPH Stock dropped -3.25% Today — RQD Quant Desk Flash. High-quality cash engine (89% profit margin, 17% return on capital) with steady institutional support.
AUPH — Aurinia Pharmaceuticals Inc: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, AUPH scores 77 out of 100, earning a B+ grade and the verdict label "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:
- Fundamental Cash Engine: 13 / 20 (ROIC 16.5%; FCF yield 5.92%). This is the cash-generation view. The ROIC and FCF yield figures indicate the business is currently producing returns, though the pillar score sits in the middle of its range.
- Whale 13F Flow: 14 / 20 (institutional accumulation and options positioning). The score reflects moderate institutional support. The source does not provide the underlying 13F holdings detail, so the magnitude of accumulation cannot be verified here.
- Insider Conviction: 17 / 20 (SEC Form 4 and Congressional PTR cluster flow). This is the strongest of the market-signal pillars, suggesting insider and disclosed-trade activity is net supportive, though the individual trades are not itemized in the source.
- Macro Regime Fit: 15 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock is modeled to move in line with the broad market, so it neither amplifies nor dampens market swings.
- Forensic Balance Sheet: 18 / 20 (Altman Z 8.33; Piotroski F 7/9; Debt/Equity 0.5). This is the highest-scoring pillar. An Altman Z of 8.33 and Piotroski F of 7 out of 9 point to strong financial health, and Debt/Equity of 0.5 indicates moderate leverage.
For a prospective investor, the upside drivers are the balance-sheet strength and the supportive insider and institutional signals. The valuation tradeoff is that the stock trades at a trailing P/E of 8 and a forward P/E of 6.7, which can reflect either undervaluation or market skepticism about durability; the source does not resolve which. The 13/20 cash-engine score signals that cash generation, while present, has not yet reached the strength of the balance-sheet pillar. These are analytical observations, not personalized advice.
Snapshot
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $283.1M | $104.9M | $287.2M | N/A | $135.7M | $80.2M | N/A |
| FY 2024 | $235.1M | $-4.7M | $5.8M | N/A | $44.4M | $83.4M | N/A |
| FY 2023 | $175.5M | $-91.7M | $-78.0M | N/A | $-33.5M | N/A | N/A |
Per the SEC financials, revenue rose from $175.5M in FY 2023 to $283.1M in FY 2025, and operating income moved from a loss of $-91.7M to $104.9M over the same span. Per the market data, gross margin is 88.5%, operating margin 37.1%, and net margin 68%, with ROIC at 16.5%. The Altman Z-Score of 8.33 and Piotroski F-Score of 7/9 are cited in the RQD pillar detail. Debt/Equity is 0.5 per that same detail; the debt line in the SEC financials is not reported.
Recent Catalysts & News Wire Analysis
- Catalyst (GREEN): A headline reports the company raised its 2026 revenue forecast to $325 million–$330 million.
- Earnings: A headline reports AUPH topped Q3 earnings estimates; a separate headline reports Q3 earnings were expected to decline, and another notes the stock price slipped after Q3 earnings strength.
- Market wire items (YELLOW): Multiple aggregator items cover market action and institutional positioning without specific new figures.
- Proprietary signals: None were provided in the Butterfly Supply-Chain Graph.
Risk watch items: the conflicting earnings headlines warrant verification against primary filings, and the source does not confirm which characterization is current.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream/downstream dependencies, sector correlations, or 2nd-order bottlenecks.
Open Questions
- What are the company's specific products, and what share of the FY 2025 revenue comes from each?
- Which Q3 earnings characterization is accurate, given conflicting headlines?
- What is the reported debt balance, and what drives the 0.5 Debt/Equity figure?
- What is the underlying 13F institutional holding change and the composition of Form 4 insider trades?
- What is the EPS for the reported fiscal periods, which is listed as N/A?
AUPH Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Aurinia Pharmaceuticals Inc (AUPH) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Aurinia Pharmaceuticals Inc (AUPH) market action, institutional positioning, and fundamental catalysts.
AUPH Bull vs. Bear Conversation Board — What's Your Call at $16.65?
🔥 Official Bull vs. Bear Debate: Is AUPH (B+ • RQD 77/100) a Buy at $17.21?
Welcome to the AUPH (Aurinia Pharmaceuticals Inc) Roar Pit. Current RQD Composite is 77/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (16.5% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on AUPH — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on AUPH, but look at what you are paying: 8.0x trailing P/E with 88.5% gross margins. Unless Aurinia Pharmaceuticals Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AUPH cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on AUPH, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $17.21 (52-wk range $12.07 - $19.25), any beat on forward guidance forces shorts and underweight funds to chase.